Comparative Pharmacology
Head-to-head clinical analysis: NORLESTRIN 28 1 50 versus OVULEN 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLESTRIN 28 1 50 versus OVULEN 28.
NORLESTRIN 28 1/50 vs OVULEN-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
Combination estrogen-progestin oral contraceptive that inhibits ovulation primarily by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, and altering cervical mucus and endometrial lining.
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
One tablet (ethinyl estradiol 0.05 mg / ethynodiol diacetate 1 mg) orally once daily for 21 days followed by 7 days placebo; continuous cycle.
None Documented
None Documented
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Ethinyl estradiol: 13-27 hours (mean ~17 hours); Norethindrone: 5-14 hours (mean ~8 hours). Clinical context: Steady state reached within 5-7 days.
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Renal: ~50% as metabolites; Fecal/biliary: ~40% as conjugated metabolites; <1% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive